Zentalis Pharmaceuticals (ZNTL) Interest & Investment Income (2019 - 2026)

Zentalis Pharmaceuticals' Interest & Investment Income history runs 8 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 198.76% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $21.5 million (up 277.43% YoY), while the FY2025 annual figure was $16.2 million, down 36.52% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $2.6 million, roughly flat from $2.6 million in the prior quarter.
• The five-year high for Interest & Investment Income was $34.9 million in Q1 2024, with the low at -$22.9 million in Q2 2024.
• The 5-year median for Interest & Investment Income is $3.2 million (2022), against an average of $4.3 million.
• The sharpest annual moves came in 2022 and 2024: Interest & Investment Income surged 3572.73% in 2022, then sank 613.66% in 2024.
• Zentalis Pharmaceuticals' Interest & Investment Income stood at $3.2 million in 2022, then jumped by 111.88% to $6.8 million in 2023, then plunged by 68.28% to $2.2 million in 2024, then increased by 20.58% to $2.6 million in 2025, then advanced by 0.15% to $2.6 million in 2026.
• Business Quant data shows ZNTL's Interest & Investment Income at $2.6 million in Q1 2026, $2.6 million in Q4 2025, and $7.0 million in Q3 2025.